Clinical Trial Update: Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating obinutuzumab for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation has completed and post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Gazyva (Obinutuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft vs. Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-03-12